Toronto -- Syneos Health experts will lead a free webinar on December 1, 2026, at 11am EST (5pm CET) on how neuroscience sponsors are changing patient identification, endpoint selection and treatment-response assessment across CNS disorders. Xtalks is hosting the session, titled "Neuroscience Development: Are We Measuring What Matters?"
Disease heterogeneity and response variability are pressuring traditional trial design
Alzheimer's disease, Parkinson's disease and psychiatry trials face disease heterogeneity, limited trial accessibility and variable treatment response. These factors are forcing sponsors to reassess how they identify patients, measure treatment effects and make development decisions. Panelists will examine why traditional measures of treatment response are being re-examined and how sponsors are evaluating endpoints that better capture clinically meaningful change.
Case examples span neurodegenerative disease, psychiatry and psychedelic medicine
The speakers will use examples from all three areas to show how patient populations, endpoints and response measures affect trial design and execution. The discussion will also cover scientific, operational and regulatory trends expected to shape neuroscience development over the next five years, including evolving trial requirements and the use of study data in development decisions.
Three Syneos Health executives are on the panel
Jason Tibbs, Global Therapeutic Head, Neuroscience & Ophthalmology, will moderate. He will be joined by Alexandria Wise and Zia Choudhry, both listed as Head of R&D and Scientific Strategy.